Evaluating a therapy for rare midgut tumours

22 Feb 2017


An experimental drug improved progression-free survival rates for patients with advanced midgut neuroendocrine tumours over a standard therapy, according to a recent global phase III clinical trial published in the New England Journal of Medicine.

Health Canal


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story